Protein Degradation

As protein degraders and molecular glues advance through clinical trials to approval, proximity-based modalities have undergone a wave of innovation and investment. The field is expanding with respect to not only chemical space but also biological – from new degraders targeting the endosome & autophagy pathways to protein stabilization and post-translational modification.

From the industry’s definitive conferences to curated clinical trial, drug and company database solutions, we provide valuable insights and meaningful connections to accelerate the path of best-in-class degraders and induced proximity-based therapeutics through the clinic and to commercial success.

We work with the leading innovators in the degrader field to bring clarity to the complexity of small molecule drug development, enabling you to stay up-to-date with scientific advancements and solve shared challenges to deliver targeted proximity-based therapeutics to tackle unmet medical needs.